AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January – September 2019 is now available on the company’s website: https://www.alzecurepharma.se/sv/section/investerare/finansiella-rapporter/
Financial information for July – September 2019
- Net sales during the period amounted to SEK 0 thousand (0).
- Earnings for the period amounted to SEK –13,382 thousand (–5,670).
- Earnings per share before and after dilution amounted to SEK –0.35 (–0.24).
- Total assets amounted to SEK 201,596 thousand (66,969) at the end of the period.
- Cash and cash equivalents amounted to SEK 196,842 thousand (65,746) at the end of the period.
Financial information for January – September 2019
- Net sales during the period amounted to SEK 0 thousand (0).
- Earnings for the period amounted to SEK –35,223 thousand (–23,018).
- Earnings per share before and after dilution amounted to SEK –0.93 (–1.14).
- Total assets amounted to SEK 201,596 thousand (66,969) at the end of the period.
- Cash and cash equivalents amounted to SEK 196,842 thousand (65,746) at the end of the period.
Significant events January – September 2019
- In March, the company initiated a new drug project in the field of pain, TrkA-NAM.
- The company was represented at the International Conference on Alzheimer’s & Parkinson’s Diseases, where it made two presentations.
- In May, the company chose to redirect the drug candidate ACD855 from cognitive dysfunction to an eye indication and ACD856 is now the primary drug candidate for cognitive dysfunction.
- At the annual general meeting on May 22, the company resolved to issue a share options program targeted at the company’s Board of Directors.
Significant events following the end of the interim period
No significant events have taken place since the end of the interim period.
Read the full interim report at: https://www.alzecurepharma.se/sv/section/investerare/finansiella-rapporter/
The information was submitted for publication, through the agency of the contact person set out below at 08.00 am CET on November 15, 2019.
For more information, please contact
Johan Sandin, CEO
Tel: +46 703 738 824
johan.sandin@alzecurepharma.com
About AlzeCure Pharma
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea and Parkinson’s disease. The company also has a project in the field of pain in early preclinical phase, TrkA-NAM. FNCA Sweden AB is the company’s certified adviser: contact +46(0)8-528 00 399, info@fnca.se. For further information, please visit our website at www.alzecurepharma.se